Sometimes the market takes a while to notice when a company's story is changing. RBC Capital Markets thinks that's exactly what's happening with Neumora Therapeutics Inc. (NMRA), and they're putting money behind that thesis.

RBC upgraded Neumora from Sector Perform to Outperform on Monday, bumping their price target from $4 to $7. The core argument? Neumora is quietly positioning itself in one of the hottest areas in biotech—obesity and metabolic disease—and investors haven't caught on yet.

The Obesity Play Takes Shape

Analyst Brian Abrahams highlighted that Neumora is building a competitive early-stage asset in the NLRP3 inhibitor class, which is showing promise across multiple large-market indications including obesity and cardiometabolic disease. The company's evolution beyond its neurology roots isn't reflected in the current market cap, he noted.

Here's where it gets interesting: Back in October, Neumora shared preclinical data for NMRA-215 from three diet-induced obesity mouse studies. The compound delivered weight loss of up to 19% as a monotherapy—comparable to semaglutide in terms of effectiveness—and an impressive 26% when combined with semaglutide.

Neumora plans to launch a clinical program for NMRA-215 in the first quarter of 2026, with 12-week human proof-of-concept data expected later that year. According to Abrahams, data in 2026 "should better define the target's potential" and could have meaningful positive implications for the company.

Beyond Obesity: The Neuropsychiatry Angle

While obesity is grabbing headlines, Neumora hasn't abandoned its neurology franchise. The company's M4 program includes NMRA-861 and NMRA-898, which could offer improved therapeutic profiles for schizophrenia and other neuropsychiatric disorders compared to current treatments.

Neumora recently initiated a Phase 1 single-ascending dose and multiple-ascending dose study of NMRA-898, with a comprehensive franchise update expected by mid-2026.

Abrahams acknowledged some caution around the later-stage neurology programs, including KOR, V1a, and M4 candidates, but suggested that with little likely baked into the current valuation, any successes would provide significant upside optionality.

The NLRP3 Opportunity

RBC Capital wrote that NLRP3 is rapidly emerging as a noteworthy metabolic and obesity target, and Neumora could start capturing value as a potential contender in this space.

Early mechanistic data and preclinical results suggest broad utility for NLRP3 inhibitors across obesity, cardiometabolic conditions, neuroinflammation, and liver and kidney diseases. So far, no significant safety issues have been reported.

The market enthusiasm is real. Recent data from Ventyx Biosciences Inc. (VTYX) demonstrated favorable cardiometabolic changes in obese patients. Even without showing weight loss, the excitement drove the stock to nearly triple, pushing market cap over $700 million.

Financial Runway and What's Ahead

Neumora has $171.5 million in cash, cash equivalents, and marketable securities, which should support operations into 2027—giving the company plenty of runway to reach those critical 2026 data readouts.

At last check Monday, NMRA stock was up 6.92% at $2.395, suggesting investors are starting to take notice of the broader opportunity.